Table 6.
SNPs in the EGFR gene associated with glioblastoma prognosis in the Swedish and Danish data set
| rs number | Region | Major allele | Genotype | No. (%) | HR (95% CI) | P value | Median survival time |
|---|---|---|---|---|---|---|---|
| rs980653 | Intron 1 | C | CC | 100 (66.2) | 1.0 | 11.7 | |
| CT | 47 (31.1) | 1.07 (0.99–1.14) | .079 | 14.2 | |||
| TT | 4 (2.6) | 0.60 (0.40–0.89) | .01* | 9.2 | |||
| rs730437 | Intron 4 | A | AA | 45 (29.6) | 1.0 | 10.8 | |
| AC | 67 (44.1) | 0.53 (0.34–0.84) | .007* | 13.2 | |||
| CC | 40 (26.3) | 0.50 (0.29–0.87) | .013* | 15.1 | |||
| rs4947986 | Intron 7 | G | GG | 72 (47.7) | 1.0 | 14.1 | |
| AG | 63 (41.7) | 1.00 (0.67–1.48) | .98 | 13.2 | |||
| AA | 16 (10.6) | 2.21 (1.17–4.18) | .014* | 9.9 | |||
| rs9642393 | Intron 19 | T | TT | 97 (64.2) | 1.0 | 12.8 | |
| CT | 47 (31.1) | 1.28 (0.86–1.90) | .226 | 13.2 | |||
| CC | 7 (4.6) | 3.44 (1.25–9.51) | .017* | 9.6 |
Hazard ratios (HRs) are adjusted for country, sex, age, surgery, radiotherapy, and chemotherapy. Number (No.) of cases analyzed varies due to missing treatment data or genotyping failure.
*Significant finding P < .05.